Introduction
Several lines of evidence implicate the IGF-1R and its ligands IGF-1 and IGF-2 in tumorigenesis (Baserga, 1999; Le Roith et al., 1999) . The IGF-1R is important for transformation and proliferation of malignant cells (Baserga, 1995; Baserga et al., 1997; Girnita et al., 2000a Girnita et al., , 2003 , is crucial for preventing apoptosis, maintaining malignancy and chemotherapy resistance (Baserga, 1995 (Baserga, , 2000 Yu and Rohan, 2000) . On the other hand, IGF-1R is not critical for growth of normal cells Yu and Rohan, 2000) .
The IGF-1R is a tetramer consisting of two ligandbinding extracellular a-subunits and two b-subunits involving a transmembrane domain, an intracellular tyrosine kinase domain and a C-terminal domain . The ligand-receptor interaction results in phosphorylation of tyrosine residues in the tyrosine kinase domain (spanning amino acid 973-1229) of the b-subunit. The crystal structure of the inactive and phosphorylated kinase domain of the IGF-1R has provided a molecular model of the IGF-1R catalytic activity (Favelyukis et al., 2001) . In unstimulated state, the activation loop (a-loop), containing the critical tyrosine (Y) residues 1131, 1135 and 1136, behaves as a pseudosubstrate that blocks the active site. Y1135 (being the first tyrosine to be phosphorylated) in the a-loop is bound in cis position in the active site, thus preventing the substrate access and occluding the ATP binding site as well. After ligand binding, the three tyrosines of the a-loop are transphosphorylated by the dimeric subunit partner. Phosphorylation of Y1135 and Y1131 destabilizes the autoinhibitory conformation of the a-loop, whereas phosphorylation of Y1136 stabilizes the catalytically optimized conformation of it (Favelyukis et al., 2001) . These changes of the a-loop conformation allow the substrate and ATP access. In turn, phosphorylation of the adaptor proteins insulin receptor substrate 1-4 (IRS-1-4) and Shc leads to activation of the phosphatidyl inositol-3 kinase (PI3K), the mitogen-activated protein kinase (MAPK) and the 14-3-3 pathways Baserga, 1995 Baserga, , 2000 Yu and Rohan, 2000) .
The importance of IGF-1R in cancer has raised therapeutic possibilities (Rohlik et al., 1987; Adams et al., 2000; Brodt et al., 2000; Girnita et al., 2000b; Kanter-Lewensohn et al., 2000; Navab et al., 2001; AllEricsson et al., 2002) . Recently, we demonstrated that the cyclolignan picropodophyllin (PPP) is an inhibitor of the IGF-1R tyrosine phosphorylation (Girnita et al., 2004) . It did not inhibit the highly homologous insulin receptor (IR) or tyrosine kinases of other major cancerrelevant growth factor receptors (Girnita et al., 2004) . PPP did not interfere with the IGF-1R tyrosine kinase at the level of ATP binding site (Girnita et al., 2004) , suggesting other mechanisms of action (e.g. inhibition at the level of receptor substrate). This is consistent with the fact that the ATP binding sites of IGF-1R and IR kinases are identical (Favelyukis et al., 2001) , implying that selective inhibition at that level cannot occur. However, there are differences outside this region of the receptor that may exploit selectivity for a substrate inhibitor (Blum et al., 2000; Parang et al., 2001) . Consistently, treatment with PPP reduced phosphorylation of Akt and Erks in IGF-1 stimulated cells (Girnita et al., 2004) . However, the effect on pAkt was considerably stronger than on pErks. The mechanisms behind PPP-induced inhibition of IGF-1R and the preferential inhibitory effect on pAkt are still unknown.
As PPP-induced IGF-1R inhibition preferentially affected PI3K/Akt, it would be interesting to analyse the mechanism behind this effect in more detail. IGF-1R has previously been shown to protect from apoptosis by inhibiting cytochrome c release through activating the PI3K/Akt pathway (Datta et al., 1997; Kulik et al., 1997; Hanahan and Weinberg, 2000) . Activated Akt has many biological roles, one of which is serine phosphorylation of Bad (Datta et al., 1997) . Upon phosphorylation Bad is dissociated from Bcl-2, and becomes sequestered by the adaptor protein 14-3-3 (Zha et al., 1996) . If Bad is not phosphorylated, proapoptotic proteins (e.g. Bak and Bax) become activated and cause cytochrome c release from mitochondria, leading to caspase-9 and then caspase-3 activation (Hanahan and Weinberg, 2000) . Active caspase-3 cleaves and inactivates, for example, the poly(ADP-ribose) polymerase (PARP), which plays an important role in maintenance of the DNA integrity (Bouchard et al., 2003) . The final result of caspase-3 activity is extensive proteolysis and degradation of DNA, which represent the final steps in the apoptotic process.
In this study we aimed to clarify the mechanisms behind PPP inhibition of the IGF-1R tyrosine kinase activity and the preferential decrease of Akt phosphorylation following PPP treatment. We also investigated the effects of PPP on the PI3K/Akt pathway to exclude that it also interferes directly with specific downstream molecules.
Results

Inhibition of IGF-1R phosphorylation
In this study we employed two different experimental conditions to investigate the effect of PPP on IGF-1R phosphorylation and downstream events: Firstly, cells were serum-starved for 24-h, then treated with PPP (or solvent only) and finally stimulated with IGF-1 before analysis. Secondly, cells growing under basal condition (in the presence of 10% FBS) were treated with PPP before analysis. The first condition is good for evaluating the specificity for IGF-1R pathway, while the second will provide information of the properties of PPP under circumstances that better resembles steady-state physiological conditions.
Regarding the IGF-1 stimulated condition we first intended to find out the optimal time of IGF-1 (50 ng/ ml) treatment to get as strong signals of IGF-1R phosphorylation as possible. Based on the results shown in Figure 1a , we decided to use 5-min stimulation time in the following experiments.
We investigated the dose-response effects of PPP on IGF-1 stimulated and basal conditions in the melanoma cell line BE and in P6 cells (murine cells overexpressing human IGF-1R). As shown in Figure 1b and c, PPP caused dose-dependent inhibition in both conditions and both cell lines.
Possible mechanism of action
To get further support for whether PPP interferes with IGF-1R autophosphorylation at the substrate level we used a recombinant IGF-1R kinase peptide involving the amino acids 956-1256 (Favelyukis et al., 2001) . (a) BE cells were serum-depleted for 24 h, after which they were stimulated with IGF-I (50 ng/ml) for 1, 3, 5, 10 and 15 min. Cellular proteins were isolated and immunoprecipitated with anti-IGF-IRb (H-60). Western blotting was performed using a phosphotyrosine antibody and after stripping the membrane, an IGF-1R antibody (C-20) (loading control). (b) Dose-response of PPP on IGF-1-stimulated IGF-1R phosphorylation. BE and P6 cells were incubated in serum-free medium for 24 h, treated with different concentrations of PPP (0, 50, 500 and 2500 nM) for 1 h and then stimulated with IGF-I 5 min before harvesting. IGF-1R phosphorylation was assayed as in (a, c). Dose-response of PPP on IGF-1R phosphorylation under basal conditions. BE and P6 cells, growing in complete medium (containing 10% FBS), were treated with different PPP doses for 1 h. IGF-1R phosphorylation was then assayed. The experiments were repeated at least three times with similar results
IGF-1R and apoptosis D Vasilcanu et al
Using a native gel, the three different tyrosine phosphorylated forms of the IGF-1R kinase could be separated and detected as described (Favelyukis et al., 2001) : 0P (non-phosphorylated); 1P (p1135); 2P (p1135 þ p1131); and 3P (p1135 þ p1131 þ p1136). At the start of this experiment, there were 0P and 1P forms, but no di-(2P) and tri-phosphorylated peptide (3P). After stimulation with ATP for different times (1-10 min), the peptide became more and more phosphorylated. At 3 and 6 min 2P and 3P appeared, respectively. After 7 min the peptides were completely tri-phosphorylated (Figure 2 ). However, when PPP was present, formation of 2P was delayed to 6 min as well as no 3P peptide had been formed at 10 min. The same result was obtained after a 20-min incubation with PPP (data not shown). This suggests that PPP completely blocks phosphorylation of tyrosine 1136 and slightly delays phosphorylation of Y1131. The experiment was repeated three times with similar results. The data suggest that PPP inhibits IGF-1R activity by specifically interfering with tyrosine phosphorylations at the level of the a-loop.
Consequently, these data would exclude the possibility that PPP is an ATP inhibitor, because such an inhibitor would not allow the formation of the 2P from the 1P peptide ( Figure 2 ). Actually, phosphorylation of tyrosine 1136, which stabilizes the kinase (Favelyukis et al., 2001) , is necessary for autophosphorylation of other tyrosine residues of the b-subunit.
Effect on IRS-1 and Akt phosphorylation
Using the same experimental conditions presented in Figure 1 we first investigated the effects of PPP on IRS-1 phosphorylation and binding of the p85 subunit of PI3K to the IGF-1R, following IGF-1 stimulation. This experiments was performed on the BE cells. As shown, IGF-1 stimulated both these events but they were dosedependently inhibited by PPP ( Figure 3) .
We now analysed the dose-response effects of PPP on phosphorylation of Akt (s473). First we could confirm that 5-min stimulation with IGF-1 also produced maximal level of pAkt ( Figure 4a ). As shown in Figure  4b and c PPP dose-dependently decreased pAkt, whereas total Akt was not affected, in both BE and P6 cells under the two experimental conditions (basal and IGF-1 stimulated). We also investigated the kinetics of pAkt inhibition in PPP-treated (500 nM) BE cells under IGF-1 stimulated conditions. As shown, a clear inhibition was seen within 1 h ( Figure 4d ). The pAkt levels in the IGF-1R negative cell line (RÀ) were, however, not affected by PPP (Figure 4d ), indicating that PPP does not interfere directly with phosphorylation of IRS-1, PI3K or Akt. We also treated the cells with the PI3K inhibitor LY294002, which drastically reduced pAkt in both BE and RÀ cells.
Effects on downstream molecules in the PI3K/Akt antiapoptotic pathway
Next, we investigated the effect of PPP on phosphorylation of Bad as well as on total Bad expression. Doseresponse experiments on BE cells, both under IGF-1 stimulated and basal conditions, could confirm pBad inhibition by PPP (Figure 5a and b). Kinetic experiments showed similar effects as on pAkt (cf Figure 4d) . Thus, 500 nM PPP reduced Bad phosphorylation rapidly ( Figure 5c ). In all three experiments PPP did not affect pBad in RÀ cells . Treatment with the PI3K inhibitor, however, reduced Bad phosphorylation in both cell lines (Figure 5c ).
The effects of PPP on procaspase-3 and PARP were also determined in a kinetic experiment on BE cells that were IGF-1 stimulated before analysis. Only a very weak effect was noticed after 60 min and first after 3 h there was a clear reduction in procaspase-3 levels ( Figure 6a ). The degradation of PARP was somewhat faster. LY294002 adequately reduced both events. The different kinetic responses on procaspase-3 and PARP may be due to a high sensitivity of PARP to active Figure 2 Effect of PPP on phosphorylation of tyrosine residues in the a-loop of the IGF-1R kinase. A baculovirus-driven cDNA construct encoding residues 956-1256 of IGF-1R b-subunit, covering the tyrosine kinase domain (spanning from amino acid 973-1229), was amplified and purified as described in Experimental procedures. Equal amounts of the peptide were subjected to a reaction buffer containing MgATP for indicated periods of time (0-10 min), with and without PPP (0.5 mM). After termination of the reactions the peptides were fractionated on a native gel to detect the phosphopeptides (nonphosphorylated, mono-phosphorylated, di-phosphorylated and tri-phosphorylated forms) Figure 3 Effect of PPP on IRS-1 phosphorylation and IGF-1R/ PI3K association. After serum depletion overnight, BE cells were treated with different concentrations of PPP (50-2500 nm) for 1 h and then stimulated with IGF-I (50 ng/ml) for 5 min. After harvesting, the cell lysate was immunoprecipitated with an antibody to IRS-1 or with an antibody to b-subunit of IGF-1R. The immunoprecipitates were then fractionated by gel electrophoresis and blotted. The IRS-1 immunoprecipitates were detected with an antibody to phospho-tyrosine (pY99) and the IGF-1R immunoprecipitates with an antibody to the p85 subunit of PI3K. A sample from the lysate was analysed for IRS-1 (loading control). The experiments were repeated at least three times with similar results
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D Vasilcanu et al caspase-3 or that PARP may also be cleaved by caspaseindependent reactions (Yu et al., 2002) . In Figure 6b , it is confirmed that PPP results in a typical fragmentation of PARP (p85). This experiment was run on BE cells that were treated at various concentrations of PPP for 1 h. Only at PPP doses of 50 nM and higher the p85 Cterminal fragment can be observed.
We measured the caspase-3 activity in BE, P6 and RÀ cells using a colorimetric assay. As shown in Figure 6c , the caspase-3 activity increased linearly after 1 h in BE and P6 cells but was only marginally elevated in the IGF-1R negative cells. Etoposide was used as a positive control. Thus, although the cleavage of procaspase-3 was detectable quite late (see Figure 6a) , it is clearly evident that caspase-3 activity appears relatively quickly.
These results provide further evidence that PPP interferes with the PI3K/apoptosis pathway in an IGF-1 specific manner. In Figure 6d , it is shown that PPP efficiently decrease viability of P6, whereas RÀ cells are not affected.
Is inhibition of Y1136 phosphorylation sufficient to reduce pAkt?
The data above suggest that PPP induces apoptosis in IGF-1R positive cells by inhibiting phosphorylation of Akt. As this response was not seen in RÀ cells it is reasonable to believe that the inhibition of pAkt is due to IGF-1R inhibition. As shown in Figure 2 , PPP caused a complete block in phosphorylation of Y1136 in the activation loop whereas Y1131 was phosphorylated. These data raise the question as to whether a specific inhibition of Y1136 phosphorylation is sufficient to reduce phosphorylation of Akt. To answer this question we used cells transiently transfected with different IGF-1R mutants in order to study possible dominantnegative effects on Akt phosphorylation. It was not possible to produce stable transfectants because all mutants resulted in massive apoptosis after 60 h, consistent with the fact that IGF-1R is essential for cell survival. Actually, dominant-negative IGF-1R has been proposed as a strategy for anticancer treatment (Brodt et al., 2000) . The IGF-1R mutants consisted of Y1131F, Y1136F, Y1131-35-36F (triple mutant) and K1003R (ATP binding site mutant). P6 and BE cells were transiently transfected with these mutants. After 24 h they were serum-depleted overnight and finally stimulated with IGF-1 for 5 min before analysis of Akt phosphorylation. As clearly shown in Figure 7a , triple and ATP mutant almost abrogated phosphorylation of Akt whereas total Akt was not affected. Y1136F caused a strong inhibition of IGF-1 stimulated pAkt but Y1131F only had a slight effect in this respect. We repeated this experiment on BE cells but stimulated with IGF-1 for various times (3-15 min). In this experiment we also involved transfection with an empty vector as a control. In contrast to IGF-1R mutant transfectants, empty vector-transfected cells were fully viable long time after the transfections (data not shown). Figure 7b demonstrates that triple and ATP mutant as well as Y1136F completely or strongly blocked phosphorylation of Akt irrespective of time of IGF-1 incubation. Y1131 had again a weak effect and the empty vector control was comparable with the untransfected control. For the samples presented in Figure 7b we also evaluated the transfection efficiency by running a semiquantitative RT-PCR analysis on RNA isolated from each transfectant. It was confirmed that cells transfected with IGF-R (wild type or mutant variants) had a strongly increased levels of the IGF-1R transcript (10-to 20-fold) compared to empty vector and untransfected controls (Figure 7a ). There was no distinguishable difference in IGF-1R gene transcription between the different IGF-1R transfectants.
Taken together, these data suggest that phosphorylation of Y1136 is important for activation of the PI3K/ Akt pathway.
Discussion
In this study we demonstrate that PPP affects activities of key molecules in the PI3K pathway and induce apoptosis in IGF-1R positive cells. In contrast, corresponding events were not affected in cells lacking IGF-1R, implying that PPP does not affect PI3K 
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pathway by co-inhibiting other growth factor receptors or by interfering directly with Akt or any of its downstream reactions. Furthermore, inhibition of phosphorylation of IGF-1R and downstream molecules of the PI3K pathway was observed at the same range of PPP concentration (IC50 ¼ 50-500 nM) under both IGF-1 stimulated and basal conditions. These results suggest that the effect of PPP on PI3K/apoptotic pathway is IGF-1R-specific. Furthermore, we could demonstrate a specific effect of PPP on the a-loop of the IGF-1R kinase domain. This mechanism may explain the preferential inhibition of the P13K/Akt pathway. PPP appears to specifically inhibit phosphorylation of Y1136 of the a-loop while sparing Y1131 and Y1135.
This finding provides further support that PPP, in contrast to most other RTK inhibitors, does not interfere with the ATP binding site. This mechanism of PPP may also explain the selectivity for the IGF-1R. Even though this specific effect of PPP on Y1136 phosphorylation may allow phosphorylation of other tyrosine residues, the absence of phosphorylated Y1136 may impair the overall kinase activity of IGF-1R. Considering the fact that the b-subunit of IGF-1R contains up to 15 tyrosine phosphorylation sites, an inhibition of Y1136 only would hardly be visible in Western blot analysis. However, as could be seen in Figure 1 , PPP caused a substantial, even though not complete, inhibition of IGF-1R tyrosine phosphoryla- A reasonable explanation for this response is the observation that phosphorylation of Y1136 is necessary for stabilization of the IGF-1RTK (Favelyukis et al., 2001) , and is therefore important to obtain full kinase activity. An incomplete activated kinase may still be able to phosphorylate some substrates (e.g. other tyrosine residues within IGF-1R) but probably not all of them.
In previous studies on effects of certain tyrphostins on IGF-1R phosphorylation and cell growth, it was observed that the IC 50 values on IGF-1R kinase was substantially higher than those on cell growth (Parrizas et al., 1997) , indicating that these inhibitors promoted growth inhibition also by interfering with downstream kinases in the growth signaling pathway. In contrast, PPP and substrate inhibitors presented recently by Blum et al. (2003) as well were nearly equipotent in this respect (Girnita et al., 2004) , supporting IGF-1R specificity. This notion is confirmed by our present findings showing that PPP exhibits essentially similar doseresponse data for all investigated downstream key events in the PI3K/Akt pathway.
Using site-mutated forms of IGF-1R, several studies have been carried out to investigate the impact of specific mutations on different properties (e.g. cell proliferation and apoptosis) in murine cell systems with the native IGF-1R poorly expressed or absent (Li et al., 1994; Stannard et al., 1995; Yam et al., 2001) . Interestingly, several of the IGF-1R mutations have also been found to mediate dominant-negative effects in cells with normal or overexpressed IGF-1R (Brodt et al., 2000) . For example, the triple mutation Y1131F/ Y1135F/Y1136F was found to inhibit the growth of mouse cells transformed by the simian virus tumor antigen (Li et al., 1994) .
In our present study, using transient transfections, we found that the triple mutant and the ATP binding site mutant completely abolished phosphorylation of Akt in P6 cells (overexpressing IGF-1R). These data are in line with data obtained by these mutants in transfected IGF-1R null mouse cells (Kato et al., 1993; Li et al., 1994; Stannard et al., 1995; Yam et al., 2001) . Interestingly, the single mutant Y1136F almost completely deleted the Akt phosphorylation, indicating that phosphorylated Y1136 may be particularly important for the PI3K pathway. The previous observations that Y1136F strongly reduces phosphorylation of IRS-1 (Li et al., 1994) provides further support for a critical role of Y1136 in the PI3K/Akt pathway. In contrast, Y1131 only reduced pAkt slightly. We could reproduce similar dominant-negative effects in the human melanoma cells. Taken together, these results suggest that the preferential inhibitory effect of PPP on the PI3K/Akt pathways, as opposed to the MAPK pathway, may be due to its inhibitory effect on Y1136 phosphorylation.
Phosphorylated Akt works as an inhibitor of apoptotic proteins and therefore plays a crucial role in growth of cancer cells. For this reason inhibition of the action of Akt has been realized as a strategy in treatment of cancer (Kim et al., 2002) . Our present study supports the role of PI3K/Akt pathway in IGF-1R dependent antiapoptosis, and provides further support for PPP as a specific inhibitor of this pathway.
Materials and methods
Reagents
PPP was synthesized (Buchardt et al., 1986) and following recrystallization its purity was 99.7%. For experimental purposes, PPP was dissolved in saline (5 mM 
Cell cultures
The human melanoma cell line BE was from R Kiessling (Karolinska Hospital, Stockholm, Sweden). The RÀ and P6 cell lines obtained from R Baserga. The RÀ fibroblasts are IGF-1R negative, derived from BALB/3T3 mouse embryo with a targeted disruption of the type 1 receptor for the insulinlike growth factors . The P6 line is a 3T3 derivative overexpressing the human IGF-1R . The cells were cultured in monolayers in standard media supplemented with 5% (P6) or 10% fetal bovine serum (FBS). P6 and RÀ cell lines were cultured in the presence of G-418 (Promega).
Dominant-negative transfectants
The BE melanoma cell line and P6 mouse fibroblasts, plated at subconfluent density in 6-cm dishes, were transiently transfected with 2 mg/ml DNA using Lipfectamine 2000, respectively, LipofectAMINE Plus (Invitrogen, Carlsbad, CA, USA), essentially as described . After 24 h the transfected cells were splited into six-well plates and cultured for an additional 24 h in the presence of 0.6 mg/ml G418. During the last 12 h, cells were starved and then stimulated for 5 min with 50 ng/ml IGF-1. Protein extracts were prepared for immunoprecipitation or Western blot analyses.
Immunoprecipitation and Western blotting
Cells were cultured to subconfluency in 6-cm plates, and then fresh medium containing 10% FBS and PPP was added for 1 h (basal condition). Alternatively the cells were serum-depleted for 24 h before addition of PPP, and then stimulated by IGF-1 (50 ng/ml) for 5 min (IGF-1 stimulated condition). For determination of IGF-1R phosphorylation, the cells were then lysed and subjected to immunoprecipitation by adding 20 ml of (Laemmli, 1970) , transferred onto nitrocellulose membranes (Hybond, Amersham, UK) and incubated with antiphosphotyrosine antibody or an antibody against the p85 subunit of PI3K. This was followed by washes with PBS and incubation with a biotinylated secondary antibody (Amersham) for 1 h. After incubation with streptavidin-labeled horse peroxidase, the detection was made (Hyperfilm-ECL, Amersham). The films were scanned by Fluor-S (BioRad) and the signals were quantified using Quantity One software (BioRad). Antibodies to IGF-1R b-subunit or actin were used as loading controls. Determination of pAkt/Akt, pBad/Bad, PARP and procaspase-3 was performed directly by Western blotting using specific antibodies.
Analysis of IGF-1R kinase peptide
A baculovirus-driven cDNA construct encoding residues 956-1256 of IGF-1R (IGF-1RK) was obtained from WT Miller (Stony Brook, New York, NY, USA) and S Hubbard (Skirball Institute of Biomolecular Medicine, New York, NY, USA). IGF-1RK was amplified in Sf9 cells as described (Favelyukis et al., 2001) , and was isolated and purified by immunoprecipitation using Seizet columns (Pierce Biotechnology, Rockford, IL, USA) packed with a goat polyclonal antibody raised against soluble IGF-1R (Ab-2, Oncogene). IGF-1RK autophosphorylation was carried out on ice for different time periods and the reactions were stopped by EDTA. The samples were run on a native gel and silver stained (Cann et al., 1998) for detection of the three different IGF-1RK phosphorylation forms (1P, 2P and 3P).
Assay of caspase-3 activity
The enzymatic activity of caspase-3 was determined by a colorimetric assay provided by BD ApoAlert Caspase-3 Colorimetric Assay Kit, which uses spectrophotometry detection at 405 nm of the cromophore p-nitroaniline (p-NA) after its cleavage by caspases from the labeled caspase-specific substrates. Units of protease activity can be quantified using a standard curve established with free p-NA.
Comparing the reading of an apoptotic sample with its corresponding noninduced control allows the determination of the fold-increase in protease activity. The experiments were performed, conforming to instructions provided by the manufacturer, in triplicates. As negative controls parallel reactions that did not contain conjugated substrates for active caspase 3 were setup.
Cell viability assay
Cell viability was assessed in triplicates by the Cell Proliferation kit II (XTT) (Roche, Mannheim, Germany) according to the manufacturer's instructions. In brief, cells were cultured in 96-wells plates in 100 ml medium. After the incubation periods, 50 ml XTT labeling mixture was added to each well and incubated for additional 1 h. Spectrophotometric absorbance was measured at 492 nm using an ELISA reader.
RT-PCR for detection of IGF-1R
Total RNA was isolated from adherent cells using RNeasy kit (Qiagen, Hilden, Germany). For the RT-PCR 500 ng total RNA was reverse transcribed to cDNA using random primers (Promega, Madison, WI, USA) in a 20 ml reaction containing 500 mM dNTP (each) (Invitrogen, Carlsbad, CA, USA) and using SuperScript II Reverse Transcriptase (Invitrogen). The primers for IGF-1R were Forward: (5 0 -GCC CGA AGG TCT GTG AGG AAG AA-3 0 and Reverse: 5 0 -GGT ACC GGT GCC AGG TTA TGA-3 0 ) (Girnita et al., 2000a) . Amplification was performed at 941C for 30 s, 601C for 30 s and 721C for 1 min for 29/31 cycles, and a final elongation at 701C for 7 min. Actin was used as an internal control of RNA integrity. The PCR products were detected by ethidium bromide staining on a 1% agarose gel and visualized in a Fluor-S MultiImager System (BioRad, Hercules, CA, USA) (Girnita et al., 2000a) .
Experimental reproducibility
All experiments were repeated al least three times with similar results.
